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Erythrocyte transmembrane flux and renal clearance of oxalate in
idiopathic calcium nephrolithiasis. An anomaly in erythrocyte oxalate
transport has been reported in patients with idiopathic calcium oxalate
nephrolithiasis. Even if clinical and experimental evidence suggests a
causal role of this cellular anomaly in calcium nephrolithiasis, a definitive
answer to this fundamental question is still lacking. We approached this
problem by searching for a possible relationship between the erythrocyte
oxalate self-exchange anomaly and the renal clearance of this anion in
stone formers. In 10 idiopathic calcium-oxalate renal stone formers, and
10 healthy subjects we evaluated the erythrocyte oxalate flux rate, and the
renal fractional clearance of oxalate by a recently described enzymathic
procedures for plasma oxalate determination. With respect to controls,
stone formers had higher oxalate flux rate in erythrocytes, and higher
oxalate renal fractional clearance with a significant direct correlation
between the two parameters. These data are compatible with a membrane
transport abnormality within the kidney of these stone formers, and the
existence of a common defect of the oxalate transport shared by both
erythrocytes and tubular renal cells. The latter may be crucial in the
pathogenesis of calcium oxalate nephrolithiasis, by modifying the renal
handling of oxalate.
An anomaly in erythrocyte (RBC) oxalate transport has been
described in patients with idiopathic calcium oxalate nephrolithi-
asis (ICN). This defect is genetically controlled, and seems to be
a risk marker of recurrent calcium nephrolithiasis [1—4]. While
clinical and experimental evidence suggests that this cellular
defect plays a causal role in calcium nephrolithiasis, our studies
have not yet provided a definitive answer to this fundamental
question, because RBCs are not renal tubular or intestinal
epithelial cells. Indeed, it seems reasonable that one should
expect to find an oxalate transport abnormality similar to that
observed in RBC in these latter cells, which are actually involved
in oxalate handling.
To date our attempts to show a relationship between the RBC
anomaly and urinary oxalate excretion have been unsuccessful [5].
However, the urinary excretion of a substance is not the choice
index for evaluating its renal handling, and renal clearance would
be more relevant. Methods to evaluate renal oxalate clearance
directly in plasma and urine have been disappointing thus far, due
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to the very low plasma levels in normal individuals. On the other
hand, indirect in vivo procedures using 14C-oxalate, are not only
complex and invasive, but also a possible source of error. The
recent availability of a new and sensitive method for the assay of
oxalate in plasma [6] led us to reconsider the problem by looking
for a possible relationship between the RBC oxalate self-exchange
anomaly and the renal clearance of this anion in stone formers.
Methods
Study protocol
Ten patients (6 males and 4 females; median age 34 years, range
21 to 60) were randomly selected from a series of recurrent
idiopathic calcium oxalate stone formers with an abnormally high
oxalate flux rate in erythrocytes (K> 0.55 x 10—2 min1) [2]. All
the study subjects had passed at least three calcium oxalate stones
in the preceding two years. The diagnosis of idiopathic calcium
oxalate nephrolithiasis was based on: a normal intravenous uro-
gram; normal blood levels of calcium, phosphorus and uric acid;
and a normal parathyroid function as indicated by the serum
parathyroid hormone concentration. None was cystinuric. The
controls were 10 healthy staff members (5 females; median age 31
years; range 24 to 48) with no family or personal history of
nephrolithiasis, and an RBC oxalate self-exchange rate within the
normal range. All patients and controls had normal renal func-
tion, sterile urine, and normal blood pressure; none had chronic
gastrointestinal disease. All gave their informed consent to the
study, according to the Helsinki Declaration. No patient or
control subject had been placed on any type of therapeutic
regimen at least in the eight weeks before the study, during which
all followed an isocaloric standard diet of this region, furnishing
approximately 75 mg of oxalate, 800 mg of calcium, 65 mg of
purine and 5 g of sodium daily.
Procedures
Fasting blood was drawn from an antecubital vein into hepa-
rinized tubes, and 24 hours urine was collected in plastic bottles
containing 10 ml 37% HC1. Plasma and urine creatinine levels
were evaluated by the creatininase methods. Oxalate was assayed
in urine by the oxalate oxidase method, and in plasma by a
recently described modification of this procedure, using a soluble,
nonimmobilized oxalate oxidase [6]. Briefly, after plasma depro-
teinization with sulfosalicilyc acid, the plasma samples were
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Stone
Controls formers
RBC oxalate flux 0.26 0.07 0.90 0.27 t = 7.35;
rate (K 10-2 p = 0.000
min1)
Urine oxalate (tmol/ 265.7 160.3 335.8 80.0 t = 1.91; n.s.
24 hr)
Plasma oxalate 1.61 0.46 1.23 0.53 t = 1.75; n.s.
(xmolJ1)
Oxalate clearance 125.6 42.1 225.4 92.4 t = 3.11;
(ml/min/l.73 m2) p = 0.006
Creatinine clearance 116.8 25.2 121.0 22.1 t = 0.40; n.s.
(ml/min/L73 m2)
Oxalate fractional 1.08 0.46 1.84 0.59 t = 3.21;
clearance p = 0.005
treated with charcoal, and then with a solution containing 3-di-
methylaminobenzoic acid, 3-methyl-2-benzo-thiazolinone hydra-
zone hydrochloride, and horseradish peroxidase. After 30 minutes
of incubation, oxalate oxidase derived from barley seedlings was
added, and the samples were further incubated for 60 minutes,
after which absorbance was measured at 590 nm. Samples and
calibrators were processed and analyzed in duplicate. Oxalate and
creatinine clearance, and the fractional clearance of oxalate were
determined.
RBC oxalate self-exchange was assayed as previously described
[21. Briefly, washed RBC were incubated for two hours in an
isotonic phosphate buffer containing 10 mmol/liter sodium ox-
alate, and 14C-oxalate disappearance from the incubation medium
was followed in time. The RBC oxalate flux was expressed as K, an
index of oxalate flux at equilibrium, calculated from the slope of
the linear relation:
ln(A — A)/(A0 — A)= —Kt
where K denotes the flux rate, and A the quantity of radioactive
oxalate at time 0, at time t and at isotope equilibrium (cc).
Statistical analysis was managed by Student's I-test for unpaired
data, and determination of the r coefficient for linear correlation.
Results
The mean values and sDs of the evaluated parameters are
reported in Table 1. As expected, ICN patients had higher
erythrocyte oxalate transport rates than controls (t = 7.35; P =
0.000). Urinary oxalate tended to be higher in the stone formers,
while plasma oxalate levels were lower, but not significantly. As a
consequence, the fractional clearance of oxalate was higher in
ICN patients than in control subjects (t = 3.11; P 0.006).
Moreover, a significant direct correlation emerged between the
erythrocyte oxalate flux rate and the renal fractional clearance of
oxalate (r = 0.81; P = 0.000; Fig. 1).
Discussion
This study shows that ICN patients with anomalous erythrocyte
oxalate self-exchange have a higher renal fractional clearance of
oxalate compared to healthy controls (Table 1), and that the
erythrocyte flux rate is closely correlated with renal oxalate
clearance (Fig. 1). These findings are compatible with a mem-
brane transport abnormality in the kidney of these ICN subjects.
This is the first, clear demonstration that the abnormality in RBC
oxalate transport which we first described in 1984 in a large
percentage of ICN patients [1], also has a counterpart at the renal
level, thus confirming the notion of a widespread cellular defect in
oxalate transport. Until now, we only had indirect evidence of a
link between the abnormal RBC oxalate transport and the oxalate
flux in different cells, in particular renal and intestinal cells. In
fact, we previously reported that a drug capable to normalize the
RBC oxalate flux was also able to reduce the urinary oxalate
excretion and the oxalate renal clearance [7]. Furthermore, there
is some evidence showing that the RBC oxalate flux shares many
features with the oxalate transport in renal tubular cells, both in
an experimental animal model [8] and in a renal epithelial cell line
[9], and in the intestinal epithelium [10].
The issue of oxalate clearance in stone formers has been very
difficult to approach because many methodological problems are
essentially related to its very low normal plasma concentration
(less than 2 imol/liter). Studies using '4C-oxalate to determine
the clearance revealed that mean values of its fractional clearance
in normal subjects range from 1.4 to 2.15 [11—15], thus indicating
a net tubular secretion of oxalate. To date, this has been the
general consensus on tubular handling of oxalate in humans.
However, results of isotope dilution methods could have been
influenced by the difficulty in obtaining steady state values of
14C-oxalate in plasma [16]. Reported estimates of oxalate renal
clearance were significantly higher in single injection than in
continuous infusion studies [15, 16]. More recently, reliable
non-isotopic methods that permit a standard renal clearance
determination have demonstrated that fractional clearance in
normal subjects ranges from 0.86 to 1.12 [17, 18], which indicates
an equilibrium between oxalate reabsorption and excretion. We
Table 1. Oxalate and derived values in idiopathic calcium-oxalate renal
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Fig. 1. Relationship between the eiythrocyte oxalate flux rate and the renal
fractional clearance of oxalate (r = 0.81; P = 0.000). Symbols are: ()
controls; (•) stone formers.
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used a reliable, recently modified enzymatic procedure to deter-
mine plasma oxalate [6], and our findings are consistent with this
premise. Fractional clearance of oxalate, at least in our healthy
controls, was close to unity. The observation that some of our
control subjects had a fractional clearance of oxalate lower than 1
suggests that tubular reabsorption might contribute to oxalate
handling in the kidney, as advanced by Wilson et al [17]. On the
other hand, fractional clearance values greater than 1 in some
controls and the much higher figures observed in stone formers
support the existence of at least one secretory site of oxalate.
Therefore, the renal handling of oxalate in humans seems to share
the same complexity observed in the rat, where Weinman et al
[19] suggested that oxalate is secreted in the foremost part of the
proximal convoluted tubule, undergoes bidirectional transport in
its mid portions, and is probably not transported further down the
tubule.
On the basis of our data showing that the oxalate fractional
clearance exceedes a mean value of 2, we cannot ascertain which
tubular site is working abnormally in ICN patients, nor can we
exclude that both are abnormal, that is, a hypofunctioning absorp-
tive and a hyperfunctioning secretory carrier. We favor the
hypothesis of a hyperfunctioning secretory transporter, similar to
that proposed for urate. In a previous study we observed that
anomalous RBC urate transport of stone formers was associated
with an abnormally low responsiveness to morphazinamide, a
phenomenon that we interpreted as evidence of a hyperfunction-
ing carrier for urate [20].
The oxalate transport defect at the erythrocyte level is related
to the chloride-bicarbonate exchanger band 3 protein (AE1)
[21—23]. Many transport systems displaying functional similarities
with RBC band 3 protein are expressed on urinary epithelial cells
[241. A protein encoded by the same gene as erythrocyte band 3
protein appears to exist in the basolateral membrane of a
intercalated cells of the collecting duct, but it is not involved in
oxalate transport [5]. In the proximal tubule, the only site where
oxalate seems to be handled by the kidney, at least two transport-
ers, an apical and a basolateral carrier, are involved in transcel-
lular oxalate movements. These transporters share many func-
tional properties with band 3 protein, but differ immunologically,
thus suggesting structural differencies [5]. Therefore, it appears
evident that most anion (oxalate) exchangers are encoded by
genes other than the AE1 gene. Very recently, however, AE1 gene
transcripts were detected in rabbit S2 proximal tubular cells, and
using antibodies against AE1 synthetic peptides corresponding to
unique nucleotide cDNA sequences, AE1 was localized in brush
border membranes [251
It is not known whether this proximal AE1 is physiologically
involved in oxalate transport. Although this possibility would
envision a widespread (RBC, proximal tubule, gut, etc.) structural
anomaly of AE1, it is still unconvincing, since we could not detect
any linkage between the RBC oxalate flux anomaly and chromo-
some 17 where the AEI gene is located [26]. On the other hand,
a number of ion transport and cell abnormalities have been
described in stone patients with abnormal RBC oxalate self-
exchange, that is, abnormal urate transport, abnormal Na/KJ2C1
cotransport activity, etc. [20, 27]. Therefore, we are faced with a
complex puzzle made up of different, apparently unrelated, cell
abnormalities, and the existence of different isoforms for different
carriers in different tissues. Our current interpretation of the
common and widespread defect underlying the anomalies ob-
served in ICN focuses on the possibility of a common abnormal
energizing step shared by many carriers, or of an abnormal (lipid)
composition of the cell membrane milieu in which transporters
work.
Beside the problem of which carrier(s) is (are) involved, we
believe that our data offer convincing evidence of a pathogenetic
link between the RBC oxalate abnormality and stone formation.
The erythrocyte anomaly in itself is probably not relevant to the
pathogenesis of ICN, however, it mirrors the existence of a
parallel anomaly at the renal level that most likely is crucial to
ICN. Several studies have demonstrated the importance of uri-
nary oxalate as a determinant of calcium oxalate precipitation,
and that small increases in oxalate urinary excretion predispose to
the formation of renal stones [5]. Nonetheless, the absence of a
correlation between 24-hour oxalate excretion and the RBC
transmembrane oxalate flux rate in a large patient series [2], and
a normal oxaluria in at least 70% of ICN patients with the RBC
oxalate anomaly, as well as the lack of any difference in the
24-hour oxalate excretion rates between patients and controls
(present data), all seem to rule out any relationship between renal
stone formation and the red cell anomaly. However, the difference
in oxalate clearance between control and stone formers may
provoke a different time course of oxalate excretion between the
two, as we demonstrated in five pairs of siblings differing for the
presence or absence of the RBC oxalate anomaly, and the
occurrence of previous stone episodes [2]. When challenged with
an oxalate load, the stone formers had higher peaks of oxaluria
and a faster excretion of the oxalate load than their healthy
control sibs. It was suggested that under physiological conditions,
exceptional (episodes of gluttony may lead to calcium stone
formation) or even normal meals might trigger in stone formers
with high oxalate clearance urine peaks that are sufficient to
induce the transitory oversaturation necessary for calcium-oxalate
crystallization, and start the lithogenetic process. The results of a
recently concluded 10-year survey in 190 stone formers support
our idea that the RBC oxalate anomaly is pathogenetically
relevant to ICN, since it was the most reliable marker of stone
recurrence [4].
In conclusion, a common defect in AE1 related proteins, or
most likely in their functional regulation, might explain both the
high oxalate self-exchange in erythrocytes and the abnormally
high clearance of oxalate in the kidney. The latter might induce a
faster excretory rate and higher urine peaks of oxalate, a phenom-
enon which is capable of triggering calcium-oxalate crystallization.
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